Grufity logoGrufity logo

BDX

252.38USD+1.55(+0.62%)Market Closed

Becton Dickinson and Co

Market Summary

USD252.38+1.55Market Closed
0.62%

BDX Alerts

BDX Stock Price

RSI Chart

Valuation

Market Cap

67.1B

Price/Earnings

38.21

Price/Sales

3.25

Price/Cashflow

27.4

MarketCap/EBT

28.31

Price/Sales

Profitability

EBT Margin

11.50%

Return on Equity

6.89%

Return on Assets

3.3%

Fundamentals

Revenue

Revenue (TTM)

18.9B

Revenue Y/Y

-20.2%

Revenue Q/Q

2.59%

Earnings

Earnings (TTM)

1.8B

Earnings Y/Y

8.68%

Earnings Q/Q

-20%

Price Action

52 Week Range

215.90276.35
(Low)(High)

Last 7 days

6.0%

Last 30 days

10.7%

Last 90 days

-0.2%

Trailing 12 Months

8.0%

Financial Health

Current Ratio

1.35

Investor Care

Dividend Yield

1.45%

Dividend/Share (TTM)

3.42

Buy Backs (1Y)

2.66%

Diluted EPS (TTM)

5.88

Peers (Alternatives to Becton Dickinson and)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-11.88% 44.84%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
14.69% -0.88%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
15.30% -16.82%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.69% 8.01%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
11.14% 17.68%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
8.87% -30.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
15.24% 17.79%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.98% -14.84%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-8.48% 5.83%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-16.73% -66.49%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
26.44% 24.39%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
9.49% -7.06%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.05% -10.97%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-6.64% -29.40%
-16.43
2.57
-8.79% -175.19%

Financials for Becton Dickinson and

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-8.5%18,87020,61320,57920,47520,248
  S&GA Expenses-4.6%4,7094,9364,9874,9034,867
  R&D Expenses-11.2%1,2561,4151,4301,4041,339
Earnings Before Taxes-24.8%1,7832,3702,3272,1072,242
Net Income1.3%1,7791,7561,9211,7662,092
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.5%52,93453,19954,78653,36353,866
  Current Assets-14.7%8,1419,54710,1528,3078,838
    Cash Equivalents-60.7%1,0062,5583,1471,9032,283
  Inventory1.9%3,2243,1633,2583,0352,866
  Net PPE0.1%6,0126,0056,4066,3846,393
  Goodwill2.7%24,62123,96824,09624,11623,901
  Current Liabilities10.3%7,8117,0806,6576,7356,626
    LT Debt, Non Current-5.4%13,88614,68317,58416,36017,110
Shareholder's Equity-0.8%25,28225,49324,52524,16023,677
  Retained Earnings0.5%15,15715,08814,41614,23313,826
  Additional Paid-In Capital0.2%19,55319,51119,49519,43519,272
Accumulated Depreciation0.0%6,4026,3996,7886,6486,549
Shares Outstanding0.0%285285292--
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations0.9%2,4712,4493,0443,7884,647
  Share Based Compensation0.4%233232239237237
Cashflow From Investing-68.7%-3,220.00-1,909.00-2,007.00-2,136.00-1,880.00
Cashflow From Financing44.6%-736.00-1,329.00-1,609.00-3,041.00-3,306.00
  Dividend Payments0.9%1,0711,0611,0551,048
  Buy Backs-83.3%5003,0001,750

Risks

What is the probability of a big loss on BDX?

27.3%


Probability that Becton Dickinson and stock will be more than 20% underwater in next one year

0%


Probability that Becton Dickinson and stock will be more than 30% underwater in next one year.

0%


Probability that Becton Dickinson and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BDX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Becton Dickinson and was unfortunately bought at previous high price.

Returns

Cumulative Returns on BDX

14.6%


10-Year Cumulative Returns

9.1%


7-Year Cumulative Returns

4.0%


5-Year Cumulative Returns

1.6%


3-Year Cumulative Returns

What are the long-term rolling returns for BDX?

FIve years rolling returns for Becton Dickinson and.

Which funds bought or sold BDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
370,000
370,000
0.38%
2022-11-23
Toroso Investments, LLC
REDUCED
-1.33
-211,000
1,735,000
0.07%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-83.33
-17,709
3,000
-%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
2,485,000
2,485,000
0.09%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
11.43
36,000
5,073,000
0.15%
2022-11-22
CVA Family Office, LLC
REDUCED
-21.21
-47,000
116,000
0.03%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
12,635,000
12,635,000
0.15%
2022-11-21
DEARBORN PARTNERS LLC
UNCHANGED
-
-11,000
212,000
0.01%
2022-11-21
Integrated Investment Consultants, LLC
SOLD OFF
-100
-208,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.98
-12,593,000
107,328,000
0.18%

1–10 of 45

Latest Funds Activity

Are funds buying BDX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BDX

Becton Dickinson and News

MarketBeat

Becton, Dickinson and Company (NYSE:BDX) Short Interest Update.30 hours ago

BDX Fair Value

Recent SEC filings of Becton Dickinson and

View All Filings
Date Filed Form Type Document
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading
Nov 29, 2022
4
Insider Trading

Latest Insider Trading transactions for BDX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-26
Khichi Samrat S.
SOLD FOR TAXES
-
-
-1,908
EVP & General Counsel
2022-11-26
Hickey David
ACQUIRED
-
-
1,816
EVP & President, Life Sciences
2022-11-26
Garrison Michael David
SOLD FOR TAXES
-
-
-617
EVP & President Medical
2022-11-26
Goette Roland
ACQUIRED
-
-
1,819
EVP and President EMEA
2022-11-26
Spoerel Thomas J
SOLD FOR TAXES
-
-
-232
VP Controller & Chief Acct Off
2022-11-26
Mocherla Pavan Kumar
SOLD FOR TAXES
-
-
-46
EVP & President Greater Asia
2022-11-26
Byrd Richard
SOLD FOR TAXES
-
-
-711
EVP & President Interventional
2022-11-26
Garrison Michael David
ACQUIRED
-
-
2,790
EVP & President Medical
2022-11-26
DelOrefice Christopher
ACQUIRED
-
-
3,087
EVP & Chief Financial Officer
2022-11-26
Polen Thomas E Jr
SOLD FOR TAXES
-
-
-10,473
Chairman, CEO and President

1–10 of 50

Thomas E. Polen
65535
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Income Statement

2022-09-30
Consolidated Statements of Income - USD ($)
$ in Millions
12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]   
Revenues$ 18,870$ 19,131$ 16,074
Cost of products sold10,39310,5009,276
Selling and administrative expense4,7094,7194,185
Research and development expense1,2561,2791,039
Acquisition-related integration and restructuring expense192179299
Other operating expense, net37203363
Total Operating Costs and Expenses16,58816,88115,161
Operating Income2,2822,250912
Interest expense(398)(469)(528)
Interest income1697
Other (expense) income, net(117)(99)23
Income from Continuing Operations Before Income Taxes1,7831,692414
Income tax provision1488862
Net Income from Continuing Operations1,6351,604352
Income from Discontinued Operations, Net of Tax144488522
Net Income1,7792,092874
Preferred stock dividends(90)(90)(107)
Net income applicable to common shareholders$ 1,689$ 2,002$ 767
Basic Earnings per Share   
Income (Loss) from Continuing Operations, Per Basic Share$ 5.42$ 5.23$ 0.88
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share0.501.691.87
Earnings Per Share, Basic5.936.922.75
Diluted Earnings per Share   
Income (Loss) from Continuing Operations, Per Diluted Share5.385.180.87
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share0.501.671.85
Diluted Earnings per Share (USD per share)$ 5.88$ 6.85$ 2.71

BDX Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Sep. 30, 2021
Current Assets  
Cash and equivalents$ 1,006$ 2,283
Restricted cash153109
Short-term investments812
Trade receivables, net2,1912,350
Inventories3,2242,743
Prepaid expenses and other1,5591,048
Current assets of discontinued operations0293
Total Current Assets8,1418,838
Property, Plant and Equipment, Net6,0126,003
Goodwill24,62123,886
Developed Technology, Net9,1089,417
Customer Relationships, Net2,6832,815
Other Intangibles, Net519541
Other Assets1,8481,945
Noncurrent Assets of Discontinued Operations0423
Total Assets52,93453,866
Current Liabilities  
Current debt obligations2,179500
Accounts payable1,6991,739
Accrued expenses2,6052,867
Salaries, wages and related items1,1711,186
Income taxes157178
Current liabilities of discontinued operations0157
Total Current Liabilities7,8116,626
Long-Term Debt13,88617,110
Long-Term Employee Benefit Obligations9021,228
Deferred Income Taxes and Other Liabilities5,0525,209
Noncurrent Liabilities of Discontinued Operations017
Commitments and Contingencies (See Note 6)
Shareholders’ Equity  
Preferred stock (See Note 4)22
Common stock — $1 par value: authorized — 640,000,000 shares; issued — 364,639,901 shares in 2022 and 2021.365365
Capital in excess of par value19,55319,272
Retained earnings15,15713,826
Deferred compensation2323
Treasury stock — 81,283,191 shares in 2022 and 80,163,949 shares in 2021.(8,330)(7,723)
Accumulated other comprehensive loss(1,488)(2,088)
Total Shareholders’ Equity25,28223,677
Total Liabilities and Shareholders’ Equity$ 52,934$ 53,866